Determinants of tumor treating field usage in patients with primary glioblastoma: A single institutional experience

This study shares, “Glioblastoma is the most common and aggressive primary malignant #BrainTumor diagnosed in adults and has a poor prognosis, with only 5%–10% of patients being alive 5 years following diagnosis. Even with the best standard of care, median overall survival has historically been only 14.6 months.

Tumor treating fields (TTFields) represent a novel therapy in the treatment of glioblastoma. TTFields deliver low-intensity, intermediate-frequency alternating electric fields that act as an antimitotic agent via transducer arrays applied to the scalp, selectively inhibiting the growth of rapidly dividing tumor cells. It has also been shown to disrupt multiple phases of the cell cycle”

In this study, “TTFields usage was explored as a continuous variable, and higher average usage was associated with longer overall survival (P = .03).”